NovoTAL (Transducer Array Layout) System – pro
The United States Food and Drug Administration (FDA) has approved the NovoTAL (Transducer Array Layout) System through a Premarket Approval (PMA) supplement. The NovoTAL System allows certified physicians to use the individual MRI data of recurrent glioblastoma multiforme (GBM) patients to optimize the field distribution and intensity of Tumor Treating Fields (TTFields) therapy. The NovoTAL System is a workstation-based propriety software tool that uses MRI head morphology, tumor size and location measurements, and tissue dielectric properties to optimize TTField distribution and intensity within the target tumor. The NovoTAL System has received FDA PMA supplement approval for use by physicians certified to prescribe the NovoTTF-100A System.
Connelly J, Hormigo A, Mohilie N, Hu J, Chaudhry A, Blondin N. Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement. BMC Cancer. 2016;16(1):842.
Chaudhry A, Benson L, Varshaver M, et al. NovoTTF™‐100A System (Tumor Treating Fields) transducer array layout planning for glioblastoma: a NovoTAL™ System user study. World J Surg Oncol. 2015;13:316.
Wenger C, Salvador R, Basser PJ, Miranda PC. Improving Tumor Treating Fields treatment efficacy in patients with glioblastoma using personalized array layouts [published online December 14, 2015]. Int J Radiat Oncol Biol Phys . 2015: